Drug Profile
Research programme: anti-PD1 antibodies - ARMO Biosciences/Ligand Pharmaceuticals
Alternative Names: AM 0001Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Open Monoclonal Technology
- Developer ARMO Biosciences; Ligand Pharmaceuticals
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD8 positive T lymphocyte stimulants; Programmed cell death-1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 22 Jun 2018 ARMO Biosciences has been acquired by Eli Lilly and Company
- 28 Aug 2017 Preclinical trials in Cancer in USA (Parenteral) before August 2017 (ARMO Biosciences pipeline, August 2017)